Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Asterias Biotherapeutics

- PMLiVE

NICE turns down first-line Keytruda for lung cancer

High cost of drug puts it above cost-effectiveness threshold

- PMLiVE

Novartis’ Zykadia nears first-line lung cancer label

Hopes to boost slow second-line sales to compete directly with Pfizer’s Xalkori and Roche’s Alecensa 

AstraZeneca AZ

Generic version of AZ’s Iressa launched in China

Qilu Pharma’s Yiruike licensed as first-line NSCLC treatment

Roche Basel Switzerland

Roche’s lung cancer drug Alecensa wins EU approval

Monotherapy conditionally approved as second-line NSCLC treatment

- PMLiVE

Merck settles PD-1 patent lawsuit with BMS and Ono

Agrees to pay $625m settlement plus royalties on sales of Keytruda until 2026

Bristol-Myers Squibb (BMS) building

BMS won’t seek quick okay for Opdivo combo in lung cancer

No longer intends to file for accelerated approval, pushing predicted approval date back to late 2018

AstraZeneca AZ

AZ tweaks immuno-oncology trials as it chases lung cancer leaders

Toughens targets for durvalumab in NSCLC monotherapy and combination study

- PMLiVE

Merck & Co’s Keytruda muscles further ahead of rivals in lung cancer

Granted accelerated review by FDA for use in combination with chemotherapy

- PMLiVE

AZ’s Tagrisso beats chemotherapy in lung cancer trial

Phase III data shows greater progression-free survival in mutation-positive NSCLC patients

National Institute for Health and Care Excellence NICE logo

NICE backs Novartis’ Afinitor and Pfizer’s Xalkori

Provisionally approves breast and lung cancer drugs after greater discounts offered

- PMLiVE

Merck gets early OK for Keytruda in first-line lung cancer

FDA fast-tracks approval of PD-1/PD-L1 inhibitor for treatment of NSCLC

Bristol-Myers Squibb (BMS) building

Keytruda, Opdivo narrow Tecentriq’s lead in bladder cancer

BMS’ drug is currently under FDA and EMA review in advanced urothelial carcinoma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links